Nisa Investment Advisors LLC Cuts Stake in DexCom, Inc. $DXCM

Nisa Investment Advisors LLC cut its position in DexCom, Inc. (NASDAQ:DXCM) by 53.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 17,919 shares of the medical device company’s stock after selling 20,529 shares during the quarter. Nisa Investment Advisors LLC’s holdings in DexCom were worth $1,189,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Twin Peaks Wealth Advisors LLC bought a new stake in shares of DexCom during the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its position in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. bought a new position in DexCom in the 3rd quarter valued at approximately $29,000. CVA Family Office LLC boosted its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the transaction, the executive vice president directly owned 112,904 shares of the company’s stock, valued at $7,321,824.40. The trade was a 1.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Truist Financial restated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price objective on shares of DexCom in a research report on Tuesday, December 16th. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.50.

DexCom Stock Performance

NASDAQ:DXCM opened at $62.22 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The business has a fifty day moving average price of $69.11 and a 200-day moving average price of $67.14. The firm has a market capitalization of $23.95 billion, a price-to-earnings ratio of 29.63, a price-to-earnings-growth ratio of 1.21 and a beta of 1.55. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 earnings per share. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.